Guidelines
The UKMS produces guidelines relating to the diagnosis, investigation and treatment of multiple myeloma.
The UKMS produces guidelines relating to the diagnosis, investigation and treatment of multiple myeloma.
They are published in association with the British Society for Haematology (BSH) and published in the British Journal of Haematology. The Chair of the UKMF Guidelines Group is a co-opted member of the BSH Haemato-oncology Task Force, which oversees the production of all BSH guidelines relating to the haematological malignancies. The writing groups of our guidelines contain members of the UKMF Executive Committee and other experts in the disease. 
 In a rapidly moving field such as the management of multiple myeloma, it is a challenge to ensure that our guidelines are up to date. They are consequently reviewed at regular intervals, and archived when they are felt to be obsolete. The UKMF Executive feels strongly that our treatment-related guidelines should recommend the best available licensed therapies, and not be affected by what treatments are funded by the NHS at the time the guidelines are written.
We believe that the UKMF/BSH myeloma guidelines are improved as a result of the closecollaboration of the group with Myeloma UK to ensure that they are ‘patient-focussed.’
Chair. Dr Simon Stern
Consultant Haematologist
Epsom and St Helier University Hospitals NHS Trust.
Secretary: Dr Kevin Boyd
Consultant Haematologist
Royal Marsden NHS Foundation Trust .